| Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) NCT01394952 | Completed | P3 | Eli Lilly and Company |
| A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes NCT03495102 | Completed | P3 | Eli Lilly and Company |
| A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin NCT00734474 | Completed | P2/P3 | Eli Lilly and Company |
| A Study in Participants With Type 2 Diabetes Mellitus NCT01064687 | Completed | P3 | Eli Lilly and Company |
| Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin NCT03684642 | Terminated | P3 | Sanofi |
| A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) NCT01191268 | Completed | P3 | Eli Lilly and Company |
| A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) NCT01075282 | Completed | P3 | Eli Lilly and Company |
| A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3) NCT01126580 | Completed | P3 | Eli Lilly and Company |
| A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus NCT01648582 | Completed | P3 | Eli Lilly and Company |
| A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes NCT01149421 | Completed | P2 | Eli Lilly and Company |
| A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus NCT01644500 | Completed | P3 | Eli Lilly and Company |
| A Study of IBI362 in Participants With Type 2 Diabetes NCT05606913 | Completed | P3 | Innovent Biologics (Suzhou) Co. Ltd. |
| A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus NCT06235086 | Completed | P3 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
| A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM NCT05680129 | Completed | P3 | Hangzhou Sciwind Biosciences Co., Ltd. |
| A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin | Active, not recruiting | P3 | Beijing Dongfang Biotech Co., Ltd. |
| A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes NCT04809220 | Completed | P3 | Eli Lilly and Company |
| A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) NCT01621178 | Completed | P3 | Eli Lilly and Company |
| A Phase 3 Study of HS-20094 in Patients With T2DM | Not yet recruiting | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | Not yet recruiting | P4 | First Affiliated Hospital of Wannan Medical College |
| A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus NCT02597049 | Completed | P3 | Eli Lilly and Company |
| A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus NCT01468181 | Completed | P3 | Eli Lilly and Company |
| A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus NCT05048719 | Completed | P2 | Eli Lilly and Company |
| A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus NCT01584232 | Completed | P3 | Eli Lilly and Company |
| A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy NCT02973100 | Completed | P2 | Eli Lilly and Company |
| A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes NCT02152371 | Completed | P3 | Eli Lilly and Company |
| Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) NCT01769378 | Completed | P3 | Eli Lilly and Company |
| A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes NCT04591626 | Completed | P3 | Eli Lilly and Company |
| A Study of LY3437943 in Participants With Type 2 Diabetes NCT04867785 | Completed | P2 | Eli Lilly and Company |
| A Study of HS-20094 in Patients With T2DM NCT06901648 | Completed | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus NCT00630825 | Completed | P2 | Eli Lilly and Company |
| A Study of IBI362 in Chinese Patients With Type 2 Diabetes NCT04965506 | Completed | P2 | Innovent Biologics (Suzhou) Co. Ltd. |
| A Study of TG103 Injection in Type 2 Diabetes Subjects NCT05348122 | Unknown | P2 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
| Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus NCT06148649 | Completed | P2 | Dongguan HEC Biopharmaceutical R&D Co., Ltd. |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin NCT07109700 | Recruiting | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India NCT05659537 | Completed | P4 | Eli Lilly and Company |
| A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes NCT07668336 | Not yet recruiting | P3 | Eli Lilly and Company |
| Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes NCT00791479 | Completed | P2 | Eli Lilly and Company |
| A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes NCT02750410 | Completed | P4 | Eli Lilly and Company |
| A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes NCT02963766 | Completed | P3 | Eli Lilly and Company |
| A Study of LY2189265 in Japanese Patients With Type 2 Diabetes NCT01001104 | Completed | P2 | Eli Lilly and Company |
| Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D NCT05140694 | Unknown | P4 | Seoul National University Bundang Hospital |
| The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. NCT05005741 | Unknown | P4 | Second Xiangya Hospital of Central South University |
| Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) NCT03648554 | Unknown | P4 | Central Hospital, Nancy, France |
| A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus NCT03962010 | Unknown | P2 | Genexine, Inc. |
| Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus NCT07677891 | Not yet recruiting | P2 | ProGen. Co., Ltd. |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) NCT06739122 | Recruiting | P3 | Eli Lilly and Company |
| Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes NCT04893148 | Unknown | P4 | Chungbuk National University Hospital |
| Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes NCT03444142 | Unknown | P4 | University of Guadalajara |
| A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes NCT03315780 | Completed | P4 | Eli Lilly and Company |